Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKinsey
Moodys
Johnson and Johnson
Boehringer Ingelheim

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Claims for Patent: 7,064,246

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,064,246
Title:Use of transposable elements for altering gene expression
Abstract: Methods of repressing expression of a recombinant gene in a cell are provided. The methods include the steps of introducing a transposase DNA binding motif into or adjacent to the gene, and introducing into the cell a transposase that is capable of binding to the transposase DNA binding motif. Methods of producing a population of cells of an organism that vary in their expression of a gene are also provided. The methods involve transfecting the cells with a first polynucleotide sequence encoding the target gene operably linked to a promoter such that the target gene is expressed in the cells, wherein the vector has at least one transposase DNA binding motif within or adjacent to the target gene; and transfecting some of the cells with a second polynucleotide encoding the transposable element operably linked to a second promoter such that the transposable element is expressed in the cells. In these methods, the target gene in the cells transfected with the second polynucleotide exhibits reduced expression when compared to the target gene in the cells that are not transfected with the second polynucleotide. Kits having a first polynucleotide with a gene and a DNA transposase binding motif in or adjacent to the gene, and a second polynucleotide comprising a gene encoding a transposase that is capable of binding to the transposase DNA binding motif are also provided.
Inventor(s): MacRae; Amy F. (St. Louis, MO)
Assignee:
Application Number:10/138,221
Patent Claims:1. A method of repressing expression of a recombinant gene in a plant cell, wherein the expression of the recombinant gene is not controlled by a promoter that is derived from a transposable element, the method comprising: a) introducing in vitro a 0.7 kB polynucleotide fragment into or adjacent to the gene, said polynucleotide fragment comprising the native configuration of Ac transposase binding motifs contained in the 0.7 kB HindIII/NcoI fragment of the native CaMV35S promoter; b) introducing the gene into the cell; and c) introducing into the cell a transposase from an Ac element.

2. The method of claim 1, wherein the transposase is introduced by transfecting the cell with a polynucleotide sequence encoding the transposase.

3. The method of claim 2, wherein the polynucleotide sequence encoding the transposase encodes a transposable element.

4. The method of claim 1, wherein the plant is a monocot.

5. The method of claim 1, wherein the plant is a dicot.

6. The method of claim 1, wherein the plant is a member of the Solanaceae family.

7. The method of claim 1, wherein the plant is a tobacco plant.

8. The method of claim 1, wherein the polynucleotide fragment is introduced into an intron or introns of the recombinant gene.

9. The method of claim 1, wherein the polynucleotide fragment is introduced into an exon or exons of the recombinant gene.

10. The method of claim 1, wherein the polynucleotide fragment is introduced into a 5' leader region of the recombinant gene.

11. The method of claim 1, wherein the polynucleotide fragment is introduced into a 3' trailer region of the recombinant gene.

12. The method of claim 1, wherein the gene is a proto-oncogene.

13. The method of claim 1, wherein the gene is a key gene in a biochemical pathway.

14. The method of claim 1, wherein the gene is operably linked to an inducible promoter.

15. The method of claim 14, wherein the inducible promoter is a chemically-induced promoter.

16. The method of claim 14 wherein the inducible promoter is induced by an environmental stress.

17. The method of claim 1, wherein the polynucleotide fragment comprises the 0.7 kB HindIII/NcoI fragment of the native CaMV35S promoter.

Details for Patent 7,064,246

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2021-05-01
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2021-05-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
Harvard Business School
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.